In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Playing the High-Stakes Pharma Game, Part I

Executive Summary

The rise in valuations of Big Biotech is due in large part to the fact that they're seen as affordable acquisition candidates for Big Pharmas in search of late-stage products. The plethora of early-stage biotech consolidation is, in contrast, generally a choice of last resort for otherwise unfinanceable companies who also can't sign worthwhile pharma deals. But the attention on late-stage programs offers opportunities for companies, like Pfizer, to strike platform technology deals which transfer technology, royalty free, from biotech to drug firm. The deals aren't cheap but these structures, impossible when platform deals were popular, allow Pfizer much greater research freedom.
Advertisement

Related Content

In Context: Aventis-Genta after Bristol-ImClone
The Foundations of High-Value Discovery Deals
The Foundations of High-Value Discovery Deals

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001267

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel